ClinicalTrials.gg
RecruitingNCT07038356EMPA-CONUpdated Nov 4, 2026

Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure

A Phase 3 interventional study of Empagliflozin 10 MG Oral Tablet [Jardiance] and Placebo in Acute Decompensated Heart Failure (ADHF), sponsored by Christian Schulze. Recruiting at 12 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Christian Schulze · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 4, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
536
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies testing empagliflozin in Heart Failure — 16 open to participants now, 22 under way, 7 of them phase 3. empagliflozin · Heart Failure.

Planned enrollment
5th of 51
536 · median 90
Started
2025
with 5 others
Phase 3
14 of 51
5 open now
Primary completion
2027-04
later than 18 of 21 live
Registered
45th of 51
by date
Lead sponsor
2 of 51
Christian Schulze

Among the 51 studies testing empagliflozin in Heart Failure, this one is the 5th largest by planned enrollment, is one of 6 that started in 2025, is one of 14 in phase 3, reaches primary completion later than 18 of the 21 other live ones, and was the 45th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 51 studies testing empagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing empagliflozin in Heart Failure, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test the hypothesis that the continuation of empagliflozin during decongestive therapy in the setting of acute decompensated and hospitalized heart failure patients is not inferior compared to therapy cessation during the acute heart failure hospitalization.

Randomized treatment (plus standard medical care) in patients with acute decompensated heart failure is one (1) tablet daily of empagliflozin 10 mg or matching placebo during the in-hospital stay (up to a maximum of 30 days), followed by treatment with empagliflozin 10 mg daily after discharge (but no later than day 31) until day 90.

The primary outcome measure is the combined hierarchical endpoint of all-cause mortality, heart failure hospitalization and worsening renal function at 90 days after admission.

Secondary outcome measures are the effects on urine output, diuretic efficiency, quality-of-life and the need for further administration of diuretics.

Participants will

  • Take one tablet of study medication once daily (day 1 to day 90)
  • Restrict fluid intake to 1.5 liters of fluid per day and record the daily fluid intake for the study from day 1 to day 6 in the patient diary
  • Measure the urine output (day 1 to day 6)
  • Fill in Questionnaires (EQ-5D-3L (3-level version of the EuroQol five dimensional descriptive system), KCCQ-12 (Kansas City Cardiomyopathy Questionnaire comprising 12 items)) on day 0 (Baseline), at hospital discharge, and on day 30
03

Conditions studied

  • Acute Decompensated Heart Failure (ADHF)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients (age ≥ 18 years) with acute decompensated heart failure (HF) according to clinical assessment on active therapy with a SGLT2 inhibitor
  • Brain Natriuretic Peptide (BNP) >100 pg/ml or N-terminal pro-BNP (NTproBNP) >300 pg/ml
  • Written obtained
  • Women of : negative pregnancy test and use of a highly effective method of

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Chronic Kidney Disease (CKD) with \<20 ml/min, or end-stage renal failure with the need for chronic dialysis treatment
  • Acute kidney injury (AKI) requiring dialysis treatment
  • Known intolerance to empagliflozin
  • Acute heart failure without signs of congestion ("dry" patient)
  • Need for hemofiltration or any other form of extracorporeal therapy
  • Previous participation in this trial or recent participation in another clinical trial (within the last 4 weeks before inclusion)
  • Identification of any causes of heart failure leading to decompensation that needs urgent management (like acute coronary syndrome, severe unstable arrhythmias, mechanical causes, acute pulmonary embolism)
  • Incapacity to understand and / or to provide written
  • Obvious uncontrolled substance abuse
  • Pregnancy, breastfeeding
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
536 participants (estimated)

Study arms

  • Placebo comparator
    control

    Randomized treatment with placebo (one tablet) daily from day 1 until the day of hospital discharge, but no longer than 30 days, followed by 10 mg empagliflozin (Jardiance, one tablet) daily until day 90.

    Drug: Placebo

  • Active comparator
    intervention

    Drug: Empagliflozin (10 mg/day), film-coated tablet Randomized treatment with 10 mg empagliflozin (Jardiance, one tablet) or placebo daily from day 1 until the day of hospital discharge, but no longer than 30 days, followed by 10 mg empagliflozin (Jardiance, one tablet) daily until day 90

    Drug: Empagliflozin 10 MG Oral Tablet [Jardiance]

Interventions

  • DrugEmpagliflozinStudies of EmpagliflozinEmpagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Randomized treatment with 10 mg empagliflozin (Jardiance, one tablet) daily from day 1 until the day of hospital discharge, but no longer than 30 days, followed by 10 mg empagliflozin (Jardiance, one tablet) daily until day 90

  • DrugPlacebo

    Randomized treatment with placebo (one tablet) daily from day 1 until the day of hospital discharge, but no longer than 30 days, followed by 10 mg empagliflozin (Jardiance, one tablet) daily until day 90

06

What researchers measure

Primary outcomes

  1. Four-step hierarchical composite primary endpoint; win ratio based on the following parameters (day 90): time to all-cause death, number of heart failure events per patient, time to first heart failure event, eGFR decrease from baseline to day 90

    The study uses a four-step hierarchical composite primary endpoint (win ratio): 1. time to all-cause death, days (day 90) 2. number of heart failure events per patient (day 90) 3. time to first heart failure event, days (day 90) 4. eGFR decrease from baseline to day 90 (with a between-patient threshold defined as ≥5 ml/min/1.73 m²)

    Time frame: day 90

Secondary outcomes

  1. Cardiovascular and total mortality on day 90

    Time frame: day 90

  2. Number of patients alive and without re-hospitalization on day 90

    Time frame: day 90

  3. Re-hospitalization after initial discharge, including reason: time to first rehospitalization after discharge

    Time frame: day 90

  4. Re-hospitalization after initial discharge, including reason: numbers of re-hospitalizations

    Time frame: day 90

  5. Number of patients with a decrease in eGFR of 5 ml/min/1.73 m² or more from baseline to day 90

    Time frame: day 90

  6. Daily and cumulative urine output (UOP, ml) measured from day 1 until day 6

    Time frame: day 1 until day 6

  7. Diuretic efficiency (ml urine per mg furosemide equivalent) from day 1 to day 6

    Time frame: day 1 until day 6

  8. Change in body weight from baseline to day 1, day 3, day 6, discharge (supposed between day 6-10), day 30, and day 90

    Time frame: day 1, day 3, day 6, discharge (supposed between day 6-10), day 30, and day 90

  9. Renal function at baseline, day 3, day 6, day 30, and day 90

    * Decrease in eGFR of \>20 ml/min/1.73 m2 * Doubling of serum creatinine * Need for renal replacement therapy * Total urinary sodium excretion and fractional excretion of sodium

    Time frame: baseline, day 3, day 6, day 30, and day 90

  10. Liver function: bilirubin (nmol/ml) at baseline, day 3, day 6, day 30, and day 90

    Time frame: baseline, day 3, day 6, day 30, and day 90

  11. Liver function: serum aminotransferases (µmol/l*s) at baseline, day 3, day 6, day 30, and day 90

    Time frame: baseline, day 3, day 6, day 30, and day 90

  12. Liver function: relevant change in coagulation status (Quick/INR, %, 3X upper limit of normal) at baseline, day 3, day 6, day 30, and day 90

    Time frame: baseline, day 3, day 6, day 30, and day 90

  13. Change in NT-proBNP (N-terminal pro Brain natriuretic peptide, pg/ml) (alternatively calculated from BNP, Brain natriuretic peptide, pg/ml) from baseline to day 6, day 30, and day 90

    Time frame: baseline to day 6, day 30, and day 90

  14. Quality of life (EQ-5D-3L questionnaire, 3-level version of the EuroQol five dimensional descriptive system ) on day 0, at hospital discharge (supposed between day 6-10), and on day 30

    Quality of life: EQ-5D-3L questionaire. The EQ-5D-3L questionnaire consists of two parts: part one contains questions about patients mobility, self-care, usual activities, pain/discomfort, anxiety/depression, with scores from 1 (no problem), 2 (some problems), and 3 (extreme problems). Part two measures patients health on a scale from 0 (the worst imaginable health) to 100 (the best imaginable health), on day 0, at hospital discharge (supposed between day 6-10), and on day 30

    Time frame: day 0, at hospital discharge (supposed between day 6-10), and on day 30

  15. Severity of heart failure (HF): KCCQ-12 questionnaire (Kansas City Cardiomyopathy Questionnaire comprising 12 items) on day 0, at hospital discharge (supposed between day 6-10), and on day 30

    KCCQ-12 questionnaire: scores range from 0 to 100, with higher scores indicating better health status, on day 0, at hospital discharge (supposed between day 6-10), and on day 30

    Time frame: day 0, at hospital discharge (supposed between day 6-10), and on day 30

  16. Intermediate Care Unit (IMC) / Intensive Care Unit (ICU) and hospital length of stay, days until discharge (supposed between day 6-10)

    Time frame: discharge (supposed between day 6-10)

  17. Single parameters of primary endpoint: time to all-cause death (day 90)

    Time frame: day 90

  18. Single parameters of primary endpoint: number of heart failure events per patient (day 90)

    Time frame: day 90

  19. Single parameters of primary endpoint: time to first heart failure event (day 90)

    Time frame: day 90

  20. Single parameters of primary endpoint: eGFR decrease from baseline to day 90 (ml/min/1.73 m²)

    Time frame: day 90

07

Study locations

12 of 12 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Apr 2027, 16 months after the start.

Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 16 months is below that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2025
First posted
Jun 26, 2025
StartActual
Dec 8, 2025
Primary completionEst.
Apr 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Deutsches Herzzentrum der Charité, Klinik für Kardiologie, Angiologie und Intensivmedizin · Berlin, GermanyNot yet recruiting→Recruiting
  • Universitätsklinikum Halle (Saale), Klinik für Innere Medizin III · Halle, GermanyNot yet recruiting→Recruiting
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Deutsches Herzzentrum der Charité, Klinik für Kardiologie, Angiologie und Intensivmedizin · Berlin, GermanyNot yet recruiting→Recruiting
    • Universitätsklinikum Halle (Saale), Klinik für Innere Medizin III · Halle, GermanyNot yet recruiting→Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07038356
Lead sponsor
Christian Schulze
Responsible party
Christian Schulze (Director of Department of Internal Medicine I at Jena University Hospital and Professor of Medicine at Friedrich Schiller University Jena, Jena University Hospital) — Sponsor-investigator
First posted
Jun 26, 2025
Start date
Dec 8, 2025
Primary completion
Apr 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion